Total Payments
$2.2M
2024 Payments
$171,177
Companies
84
Transactions
4,028
Medicare Patients
11,738
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$1.8M (83.2%)
Travel$137,139 (6.3%)
Consulting$122,244 (5.6%)
Food & Beverage$98,090 (4.5%)
Research$10,500 (0.5%)
Education$869.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 786 | 81.8% |
| Travel and Lodging | $137,139 | 637 | 6.3% |
| Consulting Fee | $122,244 | 49 | 5.6% |
| Food and Beverage | $98,090 | 2,513 | 4.5% |
| Honoraria | $22,378 | 13 | 1.0% |
| Unspecified | $10,500 | 3 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,728 | 7 | 0.3% |
| Education | $869.03 | 20 | 0.0% |
Payments by Type
General
$2.2M
4,025 transactions
Research
$10,500
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $436,722 | 605 | $0 (2024) |
| GENZYME CORPORATION | $221,629 | 264 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $205,626 | 407 | $0 (2024) |
| EMD Serono, Inc. | $203,713 | 351 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $135,136 | 100 | $0 (2024) |
| ABBVIE INC. | $106,516 | 323 | $0 (2024) |
| Genentech USA, Inc. | $101,966 | 151 | $0 (2024) |
| Amgen Inc. | $70,243 | 111 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $70,241 | 120 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $67,157 | 107 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $171,177 | 454 | TG Therapeutics, Inc. ($49,053) |
| 2023 | $198,758 | 524 | ABBVIE INC. ($31,877) |
| 2022 | $297,836 | 626 | E.R. Squibb & Sons, L.L.C. ($81,690) |
| 2021 | $229,468 | 464 | Neurocrine Biosciences, Inc. ($36,693) |
| 2020 | $241,014 | 421 | Biogen, Inc. ($61,540) |
| 2019 | $353,074 | 507 | Biogen, Inc. ($109,281) |
| 2018 | $361,475 | 548 | Biogen, Inc. ($97,815) |
| 2017 | $336,521 | 484 | GENZYME CORPORATION ($113,095) |
All Payment Transactions
4,028 individual payment records from CMS Open Payments — Page 1 of 162
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Pain Management | ||||||
| 12/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/23/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $31.30 | General |
| Category: Central Nervous System | ||||||
| 12/23/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Neurology | ||||||
| 12/23/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Pain Management | ||||||
| 12/23/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: Neurology | ||||||
| 12/23/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Pain Management | ||||||
| 12/20/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Central Nervous System | ||||||
| 12/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Neurology | ||||||
| 12/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Central Nervous System | ||||||
| 12/18/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/18/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $10.64 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,062.50 | General |
| Category: Immunology | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $350.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $180.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $585.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $334.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $107.85 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $29.49 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,618.00 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,614.00 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.13 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $10,500 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 3,299 | 19,139 | $1.5M | $539,638 |
| 2022 | 23 | 3,293 | 17,265 | $1.5M | $554,027 |
| 2021 | 23 | 3,076 | 17,002 | $1.4M | $556,845 |
| 2020 | 19 | 2,070 | 13,973 | $1.0M | $388,022 |
Total Patients
11,738
Total Services
67,379
Medicare Billing
$2.0M
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 547 | 810 | $283,550 | $91,891 | 32.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 28 | 14,795 | $114,531 | $73,324 | 64.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 426 | 426 | $191,700 | $62,181 | 32.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 277 | 678 | $134,393 | $60,992 | 45.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 270 | 274 | $116,412 | $48,047 | 41.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 415 | 595 | $178,500 | $34,899 | 19.6% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 174 | 178 | $75,650 | $28,224 | 37.3% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 170 | 170 | $51,000 | $19,359 | 38.0% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 59 | 60 | $42,000 | $15,835 | 37.7% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 55 | 56 | $25,784 | $14,477 | 56.1% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2023 | 115 | 115 | $27,324 | $13,874 | 50.8% |
| 92540 | Evaluation and testing for balance with recording | Office | 2023 | 115 | 115 | $25,574 | $11,130 | 43.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 86 | $30,100 | $10,662 | 35.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 27 | 65 | $22,750 | $10,261 | 45.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $22,000 | $8,562 | 38.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 42 | 42 | $22,050 | $8,021 | 36.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 84 | 108 | $32,400 | $7,803 | 24.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 59 | $23,600 | $7,056 | 29.9% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 169 | 169 | $12,675 | $5,446 | 43.0% |
| 92537 | Test to assess balance during warm and cool irrigation in both ears | Office | 2023 | 115 | 115 | $11,500 | $4,115 | 35.8% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2023 | 67 | 67 | $5,025 | $2,235 | 44.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 11 | $2,802 | $1,195 | 42.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 15 | 101 | $1,212 | $50.34 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 554 | 858 | $300,400 | $91,766 | 30.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 302 | 775 | $153,621 | $74,747 | 48.7% |
About Dr. Allan Perel, M.D
Dr. Allan Perel, M.D is a Neurology healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295700177.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allan Perel, M.D has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $171,177 received in 2024. These payments were reported across 4,028 transactions from 84 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Perel has provided services to 11,738 Medicare beneficiaries, totaling 67,379 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Staten Island, NY
- Active Since 02/22/2006
- Last Updated 04/25/2016
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1295700177
Products in Payments
- ZEPOSIA (Drug) $163,939
- TECFIDERA (Drug) $153,810
- AUBAGIO (Drug) $142,795
- TYSABRI (Biological) $126,550
- UBRELVY (Drug) $101,769
- ACTHAR (Biological) $91,067
- OCREVUS (Biological) $87,587
- Mavenclad (Drug) $83,063
- LEMTRADA (Drug) $78,620
- COPAXONE (Drug) $75,067
- VUMERITY (Drug) $73,317
- BRIUMVI (Drug) $65,229
- AJOVY (Biological) $65,143
- Aimovig (Biological) $61,307
- NURTEC ODT (Drug) $46,278
- Rebif (Biological) $45,534
- QULIPTA (Drug) $44,661
- UPLIZNA (Drug) $43,993
- Mavenclad (Biological) $40,135
- ONGENTYS (Drug) $39,569
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Staten Island
Jung Hahn, Md, MD
Neurology — Payments: $13,922
Neurology $13,922
Dr. Ludmila Feldman, M.d, M.D
Neurology — Payments: $10,949
Neurology $10,949
Dr. Suying Song, Md, MD
Neurology — Payments: $7,740
Neurology $7,740
Dr. Stephen Kulick, Md, MD
Neurology — Payments: $3,463
Neurology $3,463
Dr. Ida Altshuler, M.d, M.D
Neurology — Payments: $2,179
Neurology $2,179
Dr. Kamalini Asirwatham, M.d, M.D
Neurology — Payments: $1,235
Neurology $1,235